| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| E A Liashchenko, N A Skripkina, O S Levi. [Influence of levodopa, stalevo on dyskinesia in Parkinson's disease: STRIDE-PD study]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 113. issue 7 Pt 2. 2013-11-12. PMID:23994933. |
the aim of the study was to verify whether a combination of levodopa with dopa decarboxylase and catechol-o-methyltransferase inhibitors (stalevo) could delay the development of dyskinesia compared to the standard two-component drug due to the more stable concentration levodopa in the blood that provided the persistent stimulation of dopamine receptors in the striatum. |
2013-11-12 |
2023-08-12 |
Not clear |
| Scott Ayton, Jessica L George, Paul A Adlard, Ashley I Bush, Robert A Cherny, David I Finkelstei. The effect of dopamine on MPTP-induced rotarod disability. Neuroscience letters. vol 543. 2013-09-06. PMID:23562518. |
therapeutic administration of the dopamine precursor, l-dopa, alleviates these symptoms but dyskinesia's can manifest with chronic treatment. |
2013-09-06 |
2023-08-12 |
mouse |
| L Li, F-M Zho. Parallel dopamine D1 receptor activity dependence of l-Dopa-induced normal movement and dyskinesia in mice. Neuroscience. vol 236. 2013-08-26. PMID:23357114. |
parallel dopamine d1 receptor activity dependence of l-dopa-induced normal movement and dyskinesia in mice. |
2013-08-26 |
2023-08-12 |
mouse |
| Mechelle M Lewis, Guangwei Du, Michal Kidacki, Nisargkumar Patel, Michele L Shaffer, Richard B Mailman, Xuemei Huan. Higher iron in the red nucleus marks Parkinson's dyskinesia. Neurobiology of aging. vol 34. issue 5. 2013-08-13. PMID:23177595. |
dopamine cell loss and increased iron in the substantia nigra (sn) characterize parkinson's disease (pd), with cerebellar involvement increasingly recognized, particularly in motor compensation and levodopa-induced dyskinesia (lid) development. |
2013-08-13 |
2023-08-12 |
human |
| Tom H Johnston, Philippe Huot, Sammie Damude, Susan H Fox, Steven W Jones, James R Rusche, Jonathan M Brotchi. RGFP109, a histone deacetylase inhibitor attenuates L-DOPA-induced dyskinesia in the MPTP-lesioned marmoset: a proof-of-concept study. Parkinsonism & related disorders. vol 19. issue 2. 2013-08-09. PMID:22901956. |
l-3,4-dihydroxyphenylalanine (l-dopa)-induced dyskinesia (lid) are a complication of chronic dopamine replacement therapy in parkinson's disease (pd). |
2013-08-09 |
2023-08-12 |
marmoset |
| Raúl de la Fuente-Fernánde. Imaging of Dopamine in PD and Implications for Motor and Neuropsychiatric Manifestations of PD. Frontiers in neurology. vol 4. 2013-07-12. PMID:23847589. |
dopamine replacement therapy partially restores motor function but long-term treatment is often associated with motor complications (motor fluctuations and dyskinesias). |
2013-07-12 |
2023-08-12 |
human |
| María Rosario Luquin, Pedro J García-Ruiz, María José Martí, Ana Rojo, Lydia Vela, Francisco J Grandas, Mariano Bravo-Utrera, Juan Andrés Burguera, José R Chacón, Víctor M Campos-Arillo, Carmen Durán-Herrera, José Manuel Fernández-García, Rocío García-Ramos, Juan Carlos Gómez-Esteban, Javier Gutierrez, Juan Juni, Marina Mata, Juan Carlos Martínez-Castrillo, Jesús Olivares, Renée Ribacoba-Montero, Diego Santos-García, María Sierra, Caridad Valero-Merin. [Levodopa in the treatment of Parkinson's disease: myths and realties]. Revista de neurologia. vol 55. issue 11. 2013-06-20. PMID:23172094. |
in recent years we have witnessed a growing tendency to opt for the use of dopamine agonists (da) as treatment for parkinson's disease (pd), with the aim of delaying as far as possible the development of fluctuations and dyskinesias. |
2013-06-20 |
2023-08-12 |
Not clear |
| Michael C Reed, H Frederik Nijhout, Janet Bes. Computational studies of the role of serotonin in the basal ganglia. Frontiers in integrative neuroscience. vol 7. 2013-06-10. PMID:23745108. |
for example, during levodopa therapy for parkinson's disease (pd), the serotonergic projections from the dorsal raphe nucleus (drn) release dopamine as a false transmitter, and there are strong indications that this pulsatile release is connected to dyskinesias that reduce the effectiveness of the therapy. |
2013-06-10 |
2023-08-12 |
Not clear |
| Maryka Quik, Archana Mallela, Matthew Chin, J Michael McIntosh, Xiomara A Perez, Tanuja Bordi. Nicotine-mediated improvement in L-dopa-induced dyskinesias in MPTP-lesioned monkeys is dependent on dopamine nerve terminal function. Neurobiology of disease. vol 50. 2013-05-31. PMID:23009753. |
nicotine-mediated improvement in l-dopa-induced dyskinesias in mptp-lesioned monkeys is dependent on dopamine nerve terminal function. |
2013-05-31 |
2023-08-12 |
monkey |
| Karl Strecker, Michael Adamaszek, Sven Ohm, Florian Wegner, Jürgen Beck, Johannes Schwar. The 5-HT1A-receptor agonist flibanserin reduces drug-induced dyskinesia in RGS9-deficient mice. Journal of neural transmission (Vienna, Austria : 1996). vol 119. issue 11. 2013-04-18. PMID:22569849. |
mice with increased dopamine d2 receptor (drd2) signalling due to the lack of expression of the regulator of g-protein signalling 9 (rgs9) also develop dyskinesia following levodopa treatment. |
2013-04-18 |
2023-08-12 |
mouse |
| Vincenza Bagetta, Carmelo Sgobio, Valentina Pendolino, Giulia Del Papa, Alessandro Tozzi, Veronica Ghiglieri, Carmela Giampà, Elisa Zianni, Fabrizio Gardoni, Paolo Calabresi, Barbara Piccon. Rebalance of striatal NMDA/AMPA receptor ratio underlies the reduced emergence of dyskinesia during D2-like dopamine agonist treatment in experimental Parkinson's disease. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 32. issue 49. 2013-04-11. PMID:23223310. |
rebalance of striatal nmda/ampa receptor ratio underlies the reduced emergence of dyskinesia during d2-like dopamine agonist treatment in experimental parkinson's disease. |
2013-04-11 |
2023-08-12 |
rat |
| John D Gazewood, D Roxanne Richards, Karl Cleba. Parkinson disease: an update. American family physician. vol 87. issue 4. 2013-04-08. PMID:23418798. |
the combination of carbidopa and levodopa is the most effective treatment, but dopamine agonists and monoamine oxidase-b inhibitors are also effective, and are less likely to cause dyskinesias. |
2013-04-08 |
2023-08-12 |
Not clear |
| John D Gazewood, D Roxanne Richards, Karl Cleba. Parkinson disease: an update. American family physician. vol 87. issue 4. 2013-04-08. PMID:23418798. |
for patients taking carbidopa/levodopa who have motor complications, adjunctive therapy with a dopamine agonist, a monoamine oxidase-b inhibitor, or a catechol o-methyltransferase inhibitor will improve motor symptoms and functional status, but with an increase in dyskinesias. |
2013-04-08 |
2023-08-12 |
Not clear |
| Rajeswara B Mythri, Gangadharappa Harish, M M Bharat. Therapeutic potential of natural products in Parkinson's disease. Recent patents on endocrine, metabolic & immune drug discovery. vol 6. issue 3. 2013-03-14. PMID:22827714. |
although compounds such as levodopa (l-dopa) improve the striatal dopamine content, their long-term usage is associated with progressive decrease in drug response, motor fluctuations, dyskinesias and drug-induced toxicity. |
2013-03-14 |
2023-08-12 |
Not clear |
| Sherri L Thiele, Ruth Warre, Charline S Khademullah, Nusrat Fahana, Charlotte Lo, Doris Lam, Sheena Talwar, Tom H Johnston, Jonathan M Brotchie, Joanne E Nas. Generation of a model of L-DOPA-induced dyskinesia in two different mouse strains. Journal of neuroscience methods. vol 197. issue 2. 2013-02-22. PMID:21352853. |
prolonged use of the dopamine precursor l-dopa for the treatment of parkinson's disease commonly results in abnormal involuntary movements, which are termed l-dopa-induced dyskinesia (lid). |
2013-02-22 |
2023-08-12 |
mouse |
| Saki Shimizu, Yukihiro Ohn. Improving the Treatment of Parkinson's Disease: A Novel Approach by Modulating 5-HT(1A) Receptors. Aging and disease. vol 4. issue 1. 2013-02-21. PMID:23423244. |
thus, 5-ht(1a) agonists improve the various motor disorders associated with dopaminergic deficits, dyskinesia induced by chronic l-dopa treatment, mood disturbances (anxiety and depression) and dopamine agonist-induced emesis. |
2013-02-21 |
2023-08-12 |
Not clear |
| Pär Halje, Martin Tamtè, Ulrike Richter, Mohsin Mohammed, M Angela Cenci, Per Petersso. Levodopa-induced dyskinesia is strongly associated with resonant cortical oscillations. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 32. issue 47. 2013-02-01. PMID:23175810. |
the finding that abnormal cortical oscillations are a key pathophysiological mechanism calls for a revision of the prevailing hypothesis that links levodopa-induced dyskinesia to an altered sensitivity to dopamine only in the striatum. |
2013-02-01 |
2023-08-12 |
rat |
| Vijay A Mittal, Andrew Smolen, Derek J Dean, Andrea L Pelletier, Jessica Lunsford-Avery, Ashley Smit. BDNF Val66Met and spontaneous dyskinesias in non-clinical psychosis. Schizophrenia research. vol 140. issue 1-3. 2013-01-18. PMID:22766130. |
the present investigation is designed to replicate this finding and determine if brain-derived neurotrophic factor (bdnf) (implicated in striatal dopamine function) is associated with dyskinesias. |
2013-01-18 |
2023-08-12 |
Not clear |
| Joanna García, Thomas Carlsson, Máté Döbrössy, Guido Nikkhah, Christian Winkle. Impact of dopamine versus serotonin cell transplantation for the development of graft-induced dyskinesia in a rat Parkinson model. Brain research. vol 1470. 2013-01-15. PMID:22759908. |
impact of dopamine versus serotonin cell transplantation for the development of graft-induced dyskinesia in a rat parkinson model. |
2013-01-15 |
2023-08-12 |
rat |
| Gregory Porras, Amandine Berthet, Benjamin Dehay, Qin Li, Laurent Ladepeche, Elisabeth Normand, Sandra Dovero, Audrey Martinez, Evelyne Doudnikoff, Marie-Laure Martin-Négrier, Qin Chuan, Bertrand Bloch, Daniel Choquet, Eric Boué-Grabot, Laurent Groc, Erwan Bezar. PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking. The Journal of clinical investigation. vol 122. issue 11. 2013-01-15. PMID:23041629. |
psd-95 expression controls l-dopa dyskinesia through dopamine d1 receptor trafficking. |
2013-01-15 |
2023-08-12 |
rat |